Diphereline PR Dosage/Direction for Use

Prostate cancer: One intramuscular injection of Diphereline P.R. 3.75 mg every 4 weeks.
One intramuscular or subcutaneous injection of Diphereline P.R. 11.25 mg every 3 months.
Duration of the treatment: In high-risk localised or 'locally advanced hormone-dependent prostate cancer as concomitant to and following radiation therapy' clinical data have shown that radiotherapy followed by long-term androgen deprivation therapy is preferable to radiotherapy followed by short-term androgen deprivation therapy. (See Pharmacology: Pharmacodynamics under Actions.)
The treatment duration of androgen deprivation therapy recommended by medical guidances for patients with high-risk localised or locally advanced prostate cancer receiving radiotherapy is 2-3 years.
In patients who are not surgically castrated and treated with GnRH analogues for metastatic prostate cancer, treatment is usually continued upon development of castrate-resistant prostate cancer.
Endrometriosis: Duration of treatment: This depends on the initial severity of the endometriosis and the changes observed in the clinical features (functional and anatomical) during treatment.
3.75 mg: One intramuscular injection of Diphereline P.R. 3.75 mg every 4 weeks.
The treatment should not be administered for more than 6 months (see Adverse Reactions). A further course of treatment by triptorelin or by another GnRH analogue beyond 6 months should not be undertaken due to concerns about bone density losses.
11.25 mg: One intramuscular injection of Diphereline P.R. 11.25 mg every 3 months.
The subcutaneous administration has not been studied in women.
The treatment must be initiated in the first five days of the menstrual cycle.
Treatment should not be administered for more than 6 months. It is not recommended to undertake a second course of treatment by triptorelin or by another GnRH analogue.
Central precocious puberty: The treatment of children with triptorelin should be under the overall supervision of the paediatric endocrinologist or of a paediatrician or endocrinologist with expertise in the treatment of central precocious puberty.
3.75 mg: Children under 20 kg in body weight: half (1/2) a dose by intramuscular route, every 4 weeks (28 days), i.e. administer half the volume of the reconstituted suspension.
Children between 20 and 30 kg in body weight: two-thirds (2/3) of the dose by intramuscular route, every 4 weeks (28 days), i.e. administer two-thirds of the volume of the reconstituted suspension.
Children over 30 kg in body weight: one intramuscular injection every 4 weeks (28 days), i.e. administer the full volume of reconstituted suspension.
11.25 mg: Children over 20 kg in body weight: One intramuscular injection of Diphereline P.R.11.25 mg administered every 3 months.
The subcutaneous administration has not been studied in children.
Treatment should be stopped around the physiological age of puberty in boys and girls and it is recommended that treatment is not continued in girls with bone maturation of more than 12 years. There are limited data available in boys relating to the optimum time to stop treatment based on bone age, however it is advised that treatment is stopped in boys with a bone maturation age of 13-14 years.
Treatment of Uterine Fibromyomas: 3.75 mg: One intramuscular injection of Diphereline P.R. 3.75 mg every 4 weeks. The treatment must be initiated in the first five days of the menstrual cycle.
Clinical studies were conducted for durations between 3 to 4 months.
NB: The sustained release form must be injected in strict compliance with the instructions given in the package leaflet. Any incomplete injection resulting in the loss of suspension volume greater than the volume generally remaining in the injection device must be reported.
Breast Cancer: 3.75 mg: One intramuscular injection every 4 weeks in combination with tamoxifen or an aromatase inhibitor.
Triptorelin should be commenced after completion of chemotherapy, once pre-menopausal status has been confirmed.
The treatment with triptorelin must be initiated at least 6-8 weeks before starting aromatase inhibitor treatment. A minimum of two injections of triptorelin (with an interval of 4 weeks between injections) should be administered before commencement of aromatase inhibitor treatment.
During treatment with an aromatase inhibitor, triptorelin must not be interrupted to avoid rebound increases in circulating oestrogens in premenopausal women.
The recommended treatment duration for adjuvant treatment in combination with other hormonotherapy is up to 5 years. Since Diphereline P.R. 3.75 mg is a suspension of microparticles, inadvertent intravascular injection must be strictly avoided.
Administration: 11.25 mg: Diphereline P.R. 11.25 mg must not be injected intravascularly. The prolonged release form must be injected in strict compliance with the instructions given in the package insert. Any incomplete injections resulting in the loss of suspension volumes greater than the volume generally remaining in the injection syringe must be reported.